Kornitzer Capital Management Inc. KS Sells 1,029 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Kornitzer Capital Management Inc. KS cut its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 2.6% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 38,274 shares of the medical research company's stock after selling 1,029 shares during the quarter. Kornitzer Capital Management Inc. KS owned 0.14% of Bio-Rad Laboratories worth $9,322,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of BIO. GeoWealth Management LLC raised its holdings in shares of Bio-Rad Laboratories by 342.9% in the fourth quarter. GeoWealth Management LLC now owns 93 shares of the medical research company's stock valued at $31,000 after purchasing an additional 72 shares during the last quarter. Picton Mahoney Asset Management lifted its position in Bio-Rad Laboratories by 55.6% during the 4th quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company's stock worth $32,000 after buying an additional 35 shares in the last quarter. Curat Global LLC acquired a new position in shares of Bio-Rad Laboratories during the 1st quarter worth about $34,000. Allworth Financial LP grew its holdings in shares of Bio-Rad Laboratories by 260.0% in the 1st quarter. Allworth Financial LP now owns 144 shares of the medical research company's stock valued at $36,000 after acquiring an additional 104 shares in the last quarter. Finally, Brown Brothers Harriman & Co. increased its position in shares of Bio-Rad Laboratories by 2,928.6% in the fourth quarter. Brown Brothers Harriman & Co. now owns 212 shares of the medical research company's stock valued at $70,000 after acquiring an additional 205 shares during the last quarter. Institutional investors own 65.24% of the company's stock.

Bio-Rad Laboratories Stock Performance

Shares of NYSE BIO traded up $2.96 during mid-day trading on Thursday, reaching $250.22. 78,610 shares of the company were exchanged, compared to its average volume of 332,159. The company's 50-day simple moving average is $237.97 and its 200-day simple moving average is $267.88. The company has a quick ratio of 4.43, a current ratio of 5.99 and a debt-to-equity ratio of 0.18. The stock has a market capitalization of $6.81 billion, a P/E ratio of -3.28 and a beta of 0.95. Bio-Rad Laboratories, Inc. has a twelve month low of $211.43 and a twelve month high of $387.99.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical research company reported $2.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.73 by $0.81. Bio-Rad Laboratories had a negative net margin of 85.16% and a positive return on equity of 4.32%. The firm had revenue of $585.40 million during the quarter, compared to the consensus estimate of $573.01 million. During the same period last year, the business posted $2.30 earnings per share. The business's revenue for the quarter was down 4.2% compared to the same quarter last year. As a group, research analysts predict that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current year.

Analyst Upgrades and Downgrades

BIO has been the subject of a number of analyst reports. Wells Fargo & Company decreased their price target on Bio-Rad Laboratories from $260.00 to $245.00 and set an "equal weight" rating for the company in a research note on Monday, June 9th. Citigroup lowered their target price on shares of Bio-Rad Laboratories from $400.00 to $350.00 and set a "buy" rating on the stock in a report on Friday, May 2nd. Wall Street Zen cut shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research note on Sunday. Royal Bank Of Canada lowered their price objective on shares of Bio-Rad Laboratories from $409.00 to $392.00 and set an "outperform" rating on the stock in a research note on Friday, May 2nd. Finally, UBS Group cut their target price on shares of Bio-Rad Laboratories from $355.00 to $310.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $324.25.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.